Parth Kishore Shah | Health | Best Researcher Award

Published on by Civil Engineering Awards

Parth Kishore Shah | Health | Best Researcher Award

MD | SURGONE PC | United States

Parth Kishore Shah is a distinguished surgical oncologist whose research field spans thyroid cancer, parathyroid disorders, gastrointestinal malignancies, melanoma, esophageal cancer, and complex general surgical oncology. His work integrates clinical practice with translational research, emphasizing outcomes-based studies, surgical techniques, and innovations in cancer treatment. Shah has contributed to advancing knowledge in thyroid malignancy predictors, parathyroidectomy strategies, and management of neuroendocrine tumors, while also exploring molecular markers such as CTNNB-1 mutations in adrenocortical carcinoma. His international exposure at institutions like Memorial Sloan-Kettering Cancer Center and Moffitt Cancer Center strengthened his focus on advanced oncologic interventions, including heated intraperitoneal chemotherapy (HIPEC) and multidisciplinary approaches to sarcoma and melanoma. He has been actively involved in large-scale clinical trials such as the MELMART-II trial for melanoma margin assessment, DecisionDx studies for sentinel lymph node biopsy prediction, and Delphi studies addressing rare tumors like dedifferentiated liposarcoma. Shah’s extensive portfolio includes numerous oral presentations, posters, and peer-reviewed publications addressing both surgical outcomes and translational oncology. Beyond clinical research, he has played leadership roles in developing cancer treatment guidelines and initiatives such as Colorado’s Opioid Solution (CO’s CURE), focusing on safe prescribing practices and patient-centered cancer care. His scholarly impact is reflected in publications covering diverse oncologic domains, from parathyroid disease to esophageal and pancreatic cancers, while his contributions to book chapters highlight expertise in gastrointestinal and abdominal surgical oncology. With ongoing involvement in national and international cancer societies, Shah’s research continues to shape oncologic surgery, integrating evidence-based practice with innovation. His contributions extend into community education, multidisciplinary collaboration, and the mentoring of future surgeons. His academic and clinical achievements highlight a career deeply committed to improving cancer outcomes through research, education, and surgical excellence. Parth Kishore Shah’s work has earned recognition across multiple professional societies, and his scholarly influence is evident with 137 Citations, 7 Documents and an h-index of 5.

Profile: Scopus
Featured Publications:

Impact of histology classification on pathologic treatment response and overall survival in distal esophageal cancer patients: A propensity matched analysis. (2021). Diseases of the Esophagus. Advance online publication.

Junqi Niu | Clinical Medicine | Best Researcher Award

Published on by Civil Engineering Awards

Prof Junqi Niu | Clinical Medicine | Best Researcher Award

Professor, First hospital of Jilin University, China

Niu Junqi is a distinguished professor and chief of the Department of Infectious Diseases at the First Hospital of Jilin University, China. With extensive experience in hepatology, his research focuses on Hepatitis B, Hepatitis C, liver fibrosis, and hepatocellular carcinoma. He has contributed significantly to the epidemiology and therapeutic clinical trials of chronic liver diseases. Over the years, he has held esteemed positions, including Vice President of the First Hospital at Jilin University. His work has earned him numerous national and provincial recognitions. With a prolific academic record, he has authored over 180 publications and accumulated thousands of citations. He continues to lead pioneering research in liver disease treatments, making substantial contributions to the medical field.

PROFESSIONAL PROFILE

Scopus

EDUCATION 🎓

  • M.D. (1978-1982): Jilin Medical College, Jilin, China
  • M.S. (1985-1988): Norman Bethune University of Medical Sciences, Changchun, China
  • Ph.D. (1996-2000): Norman Bethune University of Medical Sciences, Changchun, China

EXPERIENCE 💼

  • 1988-1992: Assistant Professor & Physician, Norman Bethune University of Medical Sciences
  • 1992-1994: Visiting Fellow, Dept. of Medicine, St. Mary’s Hospital, Imperial College London, UK
  • 1994-1997: Associate Professor & Consultant Physician, Dept. of Infectious Diseases, Norman Bethune University of Medical Sciences
  • 1997-1999: Senior Visiting Fellow, University of Connecticut Health Center, USA
  • 1999-Present: Professor & Chief, Dept. of Infectious Diseases, First Hospital, Jilin University
  • 2001-2012: Vice President, First Hospital, Jilin University

AWARDS AND HONORS 🏆

  • 2005: Top Creative Talent Award, Jilin Province
  • 2008: Young Experts with Outstanding Contributions, China Ministry of Health
  • 2009: Top Ten Famous Doctors of Jilin University
  • 2010: Special Award of State Government
  • 2011: Senior Expert Award, Jilin Province

RESEARCH FOCUS 🔬

Niu Junqi’s research revolves around Hepatitis B, Hepatitis C, hepatocellular carcinoma, liver fibrosis, and cirrhosis. His work includes epidemiological studies, treatment innovations, and clinical trials targeting chronic liver diseases, particularly non-alcoholic fatty liver disease. His research significantly contributes to improving diagnostic accuracy, disease management, and therapeutic strategies in hepatology.

PUBLICATION TOP NOTES 📑

  • Activation of immune checkpoint OX40 inhibits HBV replication in a mouse model
  • Role of Early On-Treatment Serum HBV RNA Declines in Predicting Hepatocellular Carcinoma Risk
  • Safety, Pharmacokinetics, and Antiviral Efficacy of Capsid Assembly Modulator Freethiadine
  • Diammonium Glycyrrhizinate Ameliorates Alcohol-Induced Liver Injury
  • Safety, Pharmacokinetics, and Antiviral Efficacy of GST-HG141 in Chronic Hepatitis B Patients
  • ELISA Genotyping of Hepatitis B Virus in China with Antibodies for Genotypes B and C
  • Exosomes Target HBV-Host Interactions to Remodel the Hepatic Immune Microenvironment
  • TIR8 Protects Against Nonalcoholic Steatohepatitis by Reducing Lipotoxicity and Inflammation
  • High-Accuracy Model for HBsAg Loss in Long-Term Antiviral Therapy
  • System Analysis Identifies SOX7 as a Regulator of Hepatic Stellate Cell Activation

CONCLUSION

Niu Junqi is a leading expert in hepatology, with vast contributions to Hepatitis B & C research, liver disease treatment, and clinical trials. His pioneering work in liver fibrosis and hepatocellular carcinoma continues to shape the field, advancing both diagnosis and therapeutic strategies. With numerous awards, extensive experience, and impactful research, he remains a key figure in infectious disease and hepatology studies.